文献速递临床试验与 GCP

细胞培养四价流感疫苗在儿童中的效力研究

Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
PubMed 文献 · N Engl J Med · 2021-01-01

该研究为观察者盲法随机对照试验,在2至18岁以下儿童和青少年中比较细胞培养四价灭活流感疫苗与脑膜炎球菌ACWY疫苗,三个流感季共4514人参与。结果显示疫苗对实验室确诊流感的总效力为54.6%,对A/H1N1、A/H3N2和B型的效力分别为80.7%、42.1%和47.6%,不良事件发生率与对照组相似。

要点

  • 细胞培养四价流感疫苗对儿童流感总效力54.6%,对A/H1N1效力最高达80.7%。
  • 疫苗效力在不同年龄、性别、种族和既往接种史亚组中一致。
  • 不良事件发生率与对照疫苗组相似。

核心结论

  • 细胞培养四价灭活流感疫苗可为健康儿童和青少年提供跨流感季的保护,且不受既往流感疫苗接种影响。

研究设计与样本

  • 观察者盲法随机对照试验,在三个流感季纳入来自八个国家的2至18岁以下儿童和青少年共4514人。
  • 参与者随机接种细胞培养四价灭活流感疫苗或脑膜炎球菌ACWY疫苗,随访至少180天。
  • 2至9岁未接种过流感疫苗且分配至疫苗组的儿童在第29天接种第二剂,对照组接种安慰剂。

主要发现

  • 实验室确诊流感在疫苗组发生175/2257例(7.8%),对照组364/2252例(16.2%)。
  • 疫苗总效力为54.6%(95%CI 45.7至62.1)。
  • 对A/H1N1效力80.7%(95%CI 69.2至87.9),对A/H3N2效力42.1%(95%CI 20.3至57.9),对B型效力47.6%(95%CI 31.4至60.0)。
  • 按年龄、性别、种族和既往流感疫苗接种史分层的亚组中疫苗效力一致。
  • 疫苗组与对照组不良事件发生率相似。

临床怎么用

  • 细胞培养四价流感疫苗可作为儿童和青少年预防流感的选项,尤其对A/H1N1亚型保护效力较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cell-culture-derived influenza vaccines may enable a closer antigenic match to circulating strains of influenza virus by avoiding egg-adapted mutations. METHODS: We evaluated the efficacy of a cell-culture-derived quadrivalent inactivated influenza vaccine (IIV4c) using a Madin-Darby canine kidney cell line in children and adolescents 2 to less than 18 years of age. During three influenza seasons, participants from eight countries were enrolled in an observer-blinded, randomized clinical trial comparing IIV4c with a noninfluenza vaccine (meningococcal ACWY). All the participants received a dose of a trial vaccine. Children 2 to less than 9 years of age without previous influenza vaccination who were assigned to the IIV4c group received a second dose on day 29; their counterparts who were assigned to the comparator group received placebo. Participants were followed for at least 180 days for efficacy and safety. The presence of influenza virus in nasopharyngeal swabs from participants with influenza-like illness was confirmed by reverse-transcriptase-polymerase-chain-reaction assay and viral culture. A Cox proportional-hazards model was used to evaluate the efficacy of IIV4c as measured by the first occurrence of laboratory-confirmed type A or B influenza (primary end point). RESULTS: Between 2017 and 2019, a total of 4514 participants were randomly assigned to receive IIV4c or the meningococcal ACWY vaccine. Laboratory-confirmed influenza occurred in 175 of 2257 participants (7.8%) in the IIV4c group and in 364 of 2252 participants (16.2%) in the comparator group, and the efficacy of IIV4c was 54.6% (95% confidence interval [CI], 45.7 to 62.1). Efficacy was 80.7% (95% CI, 69.2 to 87.9) against influenza A/H1N1, 42.1% (95% CI, 20.3 to 57.9) against influenza A/H3N2, and 47.6% (95% CI, 31.4 to 60.0) against influenza B. IIV4c showed consistent vaccine efficacy in subgroups according to age, sex, race, and previous influenza vaccination. The incidences of adverse events were similar in the IIV4c group and the comparator group. CONCLUSIONS: IIV4c provided protection against influenza in healthy children and adolescents across seasons, regardless of previous influenza vaccination. (Funded by Seqirus; EudraCT number, 2016-002883-15; ClinicalTrials.gov number, NCT03165617.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Nolan T, Fortanier AC, Leav B, et al. Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children. N Engl J Med. 2021. PMID: 34644472. doi:10.1056/NEJMoa2024848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。